Peer-reviewed veterinary case report
Lomustine treatment for cats with resistant lymphoma outcomes
By Dutelle, Autumn L et al.·Published in Journal of feline medicine and surgery·2012·BluePearl Veterinary Partners, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of lomustine as a rescue agent for cats with resistant lymphoma.
- Species:
- cat
Plain-English summary
A group of 39 cats with resistant lymphoma (a type of cancer) were treated with lomustine, a chemotherapy drug, to see if it could help when other treatments had failed. The results showed that about half of the cats received more than one dose, and the average time before the cancer progressed was 39 days. Cats with gastrointestinal lymphoma had a longer time before the cancer worsened compared to those with other types. Overall, lomustine was found to be a safe and effective option for these cats.
People also search for: cat lymphoma treatment options · lomustine for cats · feline cancer prognosis · resistant lymphoma in cats · chemotherapy for cats with cancer
Abstract
This retrospective study evaluated the use of lomustine as a rescue agent for 39 cases of resistant feline lymphoma. Parameters assessed included lymphocyte cell size, number of previous chemotherapy drugs and number of previous chemotherapy protocols received, time from lymphoma diagnosis to initiation of lomustine therapy, body weight and anatomic location of lymphoma. Cell size, number of previous chemotherapy drugs, number of previous chemotherapy protocols and anatomic location were all significant prognostic factors for the progression-free interval. Twenty-one cats (54%) received more than one dose of lomustine. The overall median progression-free interval (MPFI) was 39 days (range 7-708 days). The MPFI for large versus small and intermediate cell lymphomas was 21 versus 169 days, respectively. The MPFI for gastrointestinal versus non-gastrointestinal lymphomas was 180 versus 25.5 days, respectively. Lomustine has an acceptable efficacy and safety for use as a rescue agent in feline lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22577051/